Abstract
Ulcerative colitis (UC) is a persistent, periodically reoccurring inflammatory condition
that impacts the gastrointestinal tract. Angelicone, a principal compound extracted
from Angelica sinensis, may offer a potential alternative therapeutic approach for UC through the downregulation
of inflammatory mediators. Nonetheless, the pharmacological impacts and molecular
pathways of angelicone in UC management, particularly in relation to gut microbiota,
remain unexplored. The current study scrutinized the modifications in gut microbiota
in mice afflicted with UC, induced by 3% dextran sodium sulfate (DSS), utilizing 16S
rRNA sequencing. The study demonstrated that angelicone substantially enhanced clinical
indices, mitigated colonic damage, decreased cytokine levels, and reestablished the
integrity of the intestinal epithelial barrier in UC mice. Furthermore, we discerned
distinct bacterial genera that were responsive to angelicone treatment. Importantly,
angelicone
augmented the abundance of gut microbiota and partially reinstated the disrupted intestinal
microbial composition, inclusive of the phyla Proteobacteria, Firmicutes, and Bacteroidetes. To summarize, our research offers novel perspectives into the intervention mechanisms
of angelicone in the treatment of UC.
Keywords
angelicone - gut microbiota - ulcerative colitis - dextran sodium sulfate - 16S rRNA
-
Angelica sinensis
- Apiaceae
